Attendee search 

A Biopharma company, looking for license in opportunities.

Focus-X is a preclinical stage biotech company committed to the Discovery and development,, of personalized precision medicine fulfilling the unmet needs in cancer diagnosis and treatment. We are to release the true potential of radioligand therapy by leveraging our world class peptide drug discovery platform and joining force with top radiopharmaceutical partners.

VC focused on healthcare industry

PE/VC firm

TF Capital focuses on investment in the life sciences industry, primarily investing in early stage companies with high potential. Through strategic investments in various key areas and right partnerships, TF Capital hopes to capture opportunities in the rapidly expanding Chinese life sciences market. Our investment team has vast experience and resources in industry to assist our portfolio companies.

3E Bioventures Capital is dedicated to investing in cutting-edge life sciences and biomedical technologies, with a focus on breakthrough first-in-class therapies and disruptive cross-disciplinary innovations in medical devices and diagnostics.

3E Bioventures takes on a science-driven, entrepreneur-friendly investment philosophy by working closely with companies and research institutions to develop drugs or products that have strong unmet medical needs. With offices in Beijing, Shanghai, and the San Francisco Bay Area, 3E Bioventures leverages its experience, capabilities, and network to help companies tap into markets and resources across the Pacific and advance with greater speed and capital efficiency.

The motto of 3E Bioventures Capital is captured in its name 3E: Expertise, Efficiency, Execution.

MNC

PE/VC firm

AnHeart Therapeutics is an oncology-focused clinical stage biopharmaceutical company headquartered in Hangzhou, China with offices in Beijing, Shanghai and New York. The company’s pipeline consists of three clinical stage assets: Taletrectinib, a next-gen ROS1 and NTRK inhibitor currently in Phase 2; an mIDH1 inhibitor ready for Phase 2 for low grade glioma, cholangiocarcinoma, AML and other tumors; and an AXL inhibitor in Phase 1 for overcoming resistance in various tumors.